Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Cordis SDR Email:
Why this fails: The prospect is an expert interventional cardiologist who sees 20+ device vendor emails per week. There's zero indication you understand their specific clinical challenges, quality metrics, or device procurement timing. This reads like every other vendor pitch. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring cardiologists" (job postings - everyone sees this)
Start: "Your facility's 30-day mortality rate hit 4.2% in Q3 while regional peers averaged 2.8%" (CMS quality data with specific metrics)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, facility names, exact metrics.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - competitive intelligence already pulled, peer benchmarks already analyzed, recall alerts already mapped - whether they buy or not.
These messages are ordered by quality score. The highest-scoring plays come first, regardless of whether they use public data, internal data, or both.
When FDA issues a recall for a competitor cardiovascular device, immediately alert hospitals you know use that specific device with exact inventory counts and upcoming procedure schedules. Proactive risk management assistance before their materials team discovers the recall.
Hospital risk management and materials teams must manage device safety and regulatory exposure. You're surfacing a time-sensitive patient safety issue they need to address immediately. The specificity of knowing their exact inventory count and procedure schedule proves you're not guessing - you're providing genuine value.
This play requires hospital inventory data from previous orders and FDA recall monitoring integrated with customer procedure schedules.
Combined with public FDA recall database to create hospital-specific trigger. This synthesis is unique to your sales intelligence system.When a competitor device faces FDA recall, map all hospitals in a sales territory with active inventory, prioritize by exposure level and procedure schedule, and deliver complete contact information for immediate outreach. Helps sales reps serve multiple hospitals facing urgent replacement needs simultaneously.
Sales reps can't monitor every FDA recall and cross-reference their entire territory. You're doing complex intelligence work they don't have time for - identifying which accounts need help urgently and providing ready-to-use contact details. This enables them to allocate their time effectively and serve hospitals at the moment of greatest need.
This play requires tracking competitor device placements across territories and maintaining hospital procurement contact database with procedure scheduling data.
Combined with public FDA recall data to create territory-level opportunity mapping. This competitive intelligence is proprietary to your sales organization.When a structural heart device faces FDA recall, identify all hospitals in region with active inventory, prioritize by TAVR procedure timing, and deliver actionable contact details. Enables sales reps to help multiple facilities address urgent valve replacement needs.
TAVR procedures are scheduled weeks in advance with specific device requirements. A recall creates immediate procurement crisis. You're providing territory-wide intelligence the rep can't compile alone, with ready-to-use contacts for the facilities facing the most urgent timing pressure.
This play requires monitoring structural heart device recalls and maintaining hospital contact database with TAVR procedure scheduling visibility.
Combined with public FDA data to create regional opportunity intelligence. This competitive device tracking is proprietary to your sales system.When a device used in specific procedure types faces recall, alert hospitals with exact inventory counts and upcoming procedures requiring that device. Time-sensitive planning assistance for procedure schedule continuity.
Hospitals schedule peripheral vascular procedures weeks in advance with specific device requirements. You're identifying a scheduling risk they may not have connected to the recall yet. The specificity of knowing their exact inventory and procedure schedule creates genuine urgency.
This play requires hospital inventory visibility and integration of procedure schedules with device usage patterns.
Combined with public FDA recall data to create procedure-specific risk alerts. This operational intelligence is unique to your customer relationship.When a hospital's CMS mortality or readmission rates deteriorate while regional peer facilities remain stable, provide benchmarking showing the performance gap correlates with device selection and clinical protocols. Hospitals with superior outcomes using specific devices offer protocol roadmap.
Hospital leadership faces public scrutiny on quality metrics affecting reimbursement and reputation. You're identifying a performance gap vs named competitors and implying device protocol change could help close it. The certification risk creates serious urgency beyond just metrics.
This play requires aggregated device outcome metrics from your registry (TLF rates, mortality, device success) stratified by procedure type and lesion complexity, allowing peer comparison.
Combined with public CMS surgical outcomes data to identify performance gaps specific to device choice. This outcomes synthesis is proprietary to your clinical registry.When a hospital's target lesion failure rate significantly exceeds regional peer averages, alert them to the performance gap and CMS quality penalty risk. The peer comparison makes the metric actionable and creates urgency around device performance review.
TLF is a core interventional cardiology quality metric tracked by registries and CMS. You're not just citing a number - you're showing them they're underperforming vs named regional competitors, with a clear financial consequence. The specific metric and peer context prove you understand their clinical world.
This play requires synthesizing CMS quality data with regional peer benchmarking from your device outcome registry to identify performance gaps.
Combined with public CMS data to create facility-specific quality alerts. This peer benchmarking is proprietary to your clinical registry data.Pull hospital's Q3 outcomes against named regional competitors, identify specific metrics where they're trailing, and note which competitors improved through device protocol standardization. Delivers immediate competitive intelligence they can use to build internal case for change.
Hospital leadership constantly benchmarks against local competitors for market share and reputation. You're providing ready-made competitive analysis with specific named institutions doing better, plus a hypothesis for why (device protocols). The low-commitment ask makes it easy to say yes.
This play requires synthesizing CMS quality data with knowledge of competitor device standardization initiatives at peer institutions from your field intelligence.
Combined with public CMS data to create regional competitive benchmarking. This protocol intelligence is proprietary to your sales organization.Pull hospital's outcomes across multiple quality metrics (TLF, MACE) against regional peers, identify which competitors improved recently, and connect improvement to device protocol changes. Delivers actionable competitive intelligence showing path to better outcomes.
Hospitals track multiple outcome metrics but may not have time to analyze competitive trends. You're delivering ready-made analysis showing them where they're falling behind and what successful competitors changed. Naming specific improving facilities creates urgency through competitive pressure.
This play requires aggregating CMS quality data across regional peer groups and tracking device protocol standardization initiatives from field intelligence.
Combined with public CMS outcomes data to create multi-metric competitive benchmarking. This protocol tracking is proprietary to your sales organization.When a hospital's 30-day cardiac readmission rate significantly exceeds peer averages and approaches CMS enhanced monitoring threshold, alert them to the regulatory trigger and suggest device-related complication review. Creates urgency around quality improvement before formal regulatory action.
CMS enhanced monitoring creates serious administrative burden and reputational risk. You're alerting them to regulatory exposure they may not have calculated yet, with peer context showing the gap is real. The device complication angle provides actionable next step.
This play requires tracking CMS readmission data and identifying peer hospital groups for meaningful comparison, plus device-related complication visibility from your registry.
Combined with public CMS data to create regulatory risk alerts. This peer grouping and complication analysis is proprietary to your clinical intelligence.When a competitor stent faces FDA recall, map all hospitals in region with active inventory, prioritize by exposure level (unit count) and procedure schedule, and deliver complete contact information starting with highest-priority account. Helps sales reps allocate their time to serve hospitals with most urgent needs.
Sales reps can't manually cross-reference FDA recalls against their entire territory and prioritize by urgency. You're providing territory-level intelligence with ready-to-use contact details and clear prioritization logic. This enables them to help the most exposed hospitals first.
This play requires monitoring FDA recalls and mapping them to hospital inventory databases with procedure scheduling data across territories.
Combined with public FDA data to create territory-level opportunity intelligence. This competitive device tracking is proprietary to your sales system.Old way: Spray generic messages at job titles. Hope someone replies.
New way: Use public data (CMS quality metrics, FDA recalls) combined with internal intelligence (device usage tracking, outcomes registry) to find hospitals in specific high-urgency situations. Then mirror that situation back to them with evidence.
Why this works: When you lead with "Your facility's TLF rate hit 4.2% while peers averaged 2.8%" instead of "We have innovative cardiovascular devices," you're not another sales email. You're the person who did the homework and understands their specific clinical and regulatory pressure.
The messages above aren't templates. They're examples of what happens when you combine real data sources (CMS outcomes, FDA recalls, internal registry data) with specific situations (quality metric decline, competitor device recalls, peer performance gaps). Your team can replicate this using the data recipes in each play.
Every play traces back to verifiable data. Here are the sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| CMS Hospital Readmissions Reduction Program & Cardiac Outcomes Data | hospital_name, 30-day_mortality_rate, 30-day_readmission_rate, condition, state, city | Quality metric deterioration alerts, peer benchmarking, regulatory risk triggers |
| STS Public Reporting - Adult Cardiac Surgery Database | hospital_name, procedure_type, mortality_rate, morbidity_rate, surgeon_name, volume_metrics | Surgical outcomes benchmarking, volume decline detection |
| ACC National Cardiovascular Data Registry (NCDR) - CathPCI Registry | hospital_name, PCI_procedure_volume, patient_outcomes, stent_type, intervention_results, device_characteristics | PCI outcome benchmarking, device performance tracking |
| FDA Medical Device Recalls and Early Alerts Database | device_type, recall_class, reason, date, affected_hospitals, risk_assessment | Competitor device recall alerts, replacement opportunity identification |
| CMS National Procedure Volume Data - PCI and Coronary Intervention Trends | procedure_type, annual_volume, beneficiary_count, trend_direction, geographic_distribution | Volume growth detection, program expansion signals |
| State Hospital Licensing and Cardiac Cath Lab Certification Data | facility_name, lab_category, license_expiration, compliance_status, procedure_authorization | License renewal cycle timing, new certification alerts |
| Internal Hospital Inventory Database | hospital_device_usage_tracking, inventory_counts, procedure_schedules | Competitor device usage tracking, recall exposure mapping |
| Internal Device Outcome Registry (SELUTION Registry) | aggregated_TLF_rates, mortality_metrics, device_success_rates, procedure_type, lesion_complexity | Peer outcome benchmarking, protocol performance comparison |